Calcitonin gene-related peptide (CGRP) monoclonal antibodies have emerged as effective preventive treatments for episodic and chronic migraine, but concerns have been raised regarding their potential cardiovascular safety profile, particularly the risk of hypertension. Here, CALCA is linked to Hypertension.